Company Overview

MIRA Pharmaceuticals, Inc. is a U.S.-based preclinical-stage pharmaceutical company focused on the development of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The company operates within the biotechnology and specialty pharmaceutical industries, with research efforts centered on synthetic cannabinoid analogs and ketamine-based compounds intended to address conditions with significant unmet medical needs. Public filings and corporate disclosures indicate that MIRA’s primary value drivers are its intellectual property portfolio, drug-development pipeline, and commercialization potential for proprietary compounds rather than current product sales or operating revenue.

The company’s lead development programs have included Ketamir-2, a ketamine analog being evaluated for potential applications in neuropathic pain and depressive disorders, and cannabinoid-related compounds designed to target anxiety, cognitive impairment, and metabolic dysfunction. MIRA positions itself around the development of orally administered therapies intended to reduce side effects commonly associated with existing treatments while preserving therapeutic efficacy. The company evolved from an early-stage biotech platform into a publicly traded pharmaceutical development company through capital markets financing and expanded research initiatives focused on central nervous system disorders.

Business Operations

MIRA Pharmaceuticals primarily operates through a single biotechnology research and development platform focused on proprietary drug candidates and intellectual property generation. As disclosed in public filings, the company does not currently generate material commercial revenue and instead finances operations through equity offerings, investor funding, and public market activity. Its operational model centers on preclinical research, formulation development, licensing opportunities, regulatory preparation, and collaboration with third-party laboratories and contract research organizations.

The company’s principal assets include its patent applications, compound formulations, and development-stage therapeutic programs. Operations are concentrated in the United States, although certain research, testing, and manufacturing support activities may involve external partners and service providers. Publicly available information indicates that MIRA has emphasized development of oral pharmaceutical candidates intended to improve patient compliance and safety profiles relative to existing treatments in the pain-management and neuropsychiatric markets. Data regarding major joint ventures or large-scale commercial subsidiaries remains limited in publicly available filings.

Strategic Position & Investments

MIRA Pharmaceuticals’ strategic direction is centered on advancing differentiated central nervous system and metabolic therapies through preclinical and clinical development milestones. The company has emphasized expanding its intellectual property estate and pursuing therapeutic candidates that may offer advantages over traditional opioids, standard ketamine therapies, or conventional cannabinoid-based treatments. Growth initiatives have included continued investment in research and development, patent filings, and regulatory advancement activities intended to support future clinical trials.

The company has also explored opportunities tied to emerging pharmaceutical sectors involving synthetic cannabinoids, neuropsychiatric therapeutics, and non-opioid pain management. Public disclosures have referenced ongoing development and evaluation of proprietary compounds rather than large-scale acquisitions or diversified investment holdings. Information regarding significant portfolio companies or extensive subsidiary structures is limited based on available public sources, and some pipeline-stage claims remain subject to further clinical validation and regulatory review.

Geographic Footprint

MIRA Pharmaceuticals is headquartered in the United States and primarily conducts its corporate and development activities domestically. Its market presence is principally tied to U.S. capital markets through its Nasdaq listing and investor outreach within the biotechnology sector. The company’s operational footprint appears concentrated in North America, particularly in research management, intellectual property administration, and strategic corporate functions.

Although MIRA does not currently report broad international commercial operations, its therapeutic development strategy targets global pharmaceutical markets, especially in areas such as chronic pain, depression, anxiety disorders, and metabolic disease. The company’s research and development activities may involve international scientific vendors or contract organizations, but publicly available disclosures do not indicate a major multinational operating infrastructure at this stage.

Leadership & Governance

MIRA Pharmaceuticals is led by executives with backgrounds in biotechnology, pharmaceuticals, finance, and corporate development. Leadership communications and public statements have emphasized innovation in neuropsychiatric therapeutics, advancement of proprietary intellectual property, and development of safer alternatives to existing treatment options in pain management and mental health care. The company operates under a publicly traded corporate governance structure consistent with Nasdaq-listed biotechnology issuers.

Key executives and leadership figures include:

• Eitan Gorlin – Chief Executive Officer
• James Young – Chief Financial Officer
• Douglas K. Gordon – Chairman of the Board

Additional leadership and advisory participation may change over time based on corporate filings and governance updates. Publicly available information regarding founder attribution and broader executive composition is limited in certain disclosures, and some details are inconclusive based on available public sources.